NCT06293742 - ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

ECC5004

ECC5004 tablet will be administered orally.

DRUG

Midazolam

Midazolam will be administered orally.

DRUG

Rosuvastatin

Rosuvastatin will be administered orally.

DRUG

Digoxin

Digoxin will be administered orally.

DRUG

Atorvastatin

Atorvastatin will be administered orally.

Trial Locations (1)

Eccogene Investigational Site, Anaheim